Blog
RSS FeedPosted by Michael Wonder on 15 Jan 2021
NICE backs GSK’s Zejula in advanced ovarian cancer
15 January 2021 - The UK’s NICE has recommended the use of GlaxoSmithKline’s Zejula (niraparib) on the NHS for women ...
Posted by Michael Wonder on 08 Jan 2021
NICE no for BMS’ Opdivo for head and neck cancer
8 January 2021 - The UK’s NICE has turned down Bristol Myers Squibb’s immunotherapy Opdivo (nivolumab) for recurrent or metastatic ...
Posted by Michael Wonder on 16 Dec 2020
NICE recommends Novartis’ wet AMD drug Beovu
16 December 2020 - The UK’s NICE has recommended Novartis’ anti-VEGF treatment Beovu (brolucizumab) for routine NHS use in wet ...
Posted by Michael Wonder on 14 Dec 2020
NICE u-turn on Novartis' migraine drug Aimovig
14 December 2020 - In a rare move, NICE has reconsidered its position on Novartis migraine prevention treatment Aimovig (erenumab), ...
Posted by Michael Wonder on 11 Dec 2020
Alunbrig scores NICE backing for ALK positive lung cancer
11 December 2020 - Takeda’s Alunbrig (brigatinib) has been recommended by the UK’s NICE for patients with ALK positive advanced ...
Posted by Michael Wonder on 01 Dec 2020
Innovative technology to detect abnormal heart rhythms recommended by NICE for NHS use while further data is collected
1 December 2020 - Zio ZT is the first assessment, via the NICE digital health technologies guidance development pilot project, to ...
Posted by Michael Wonder on 25 Nov 2020
Merck racks up another NICE recommendation for Keytruda
25 November 2020 - That makes it number 12. ...
Posted by Michael Wonder on 25 Nov 2020
NICE publishes final guidance on Nubeqa
25 November 2020 - NICE has completed its assessment of darolutamide for use in combination with androgen deprivation therapy for ...
Posted by Michael Wonder on 24 Nov 2020
NICE backs Braftovi for BRAF positive colorectal cancer
24 November 2020 - NICE has back Pierre Fabre’s Braftovi plus cetuximab for the treatment of BRAF positive metastatic colorectal ...
Posted by Michael Wonder on 24 Nov 2020
New option for people with difficult-to-treat multiple myeloma is recommended for use in Cancer Drugs Fund by NICE
24 November 2020 - Around 5,700 cases of multiple myeloma are diagnosed each year in the UK. ...
Posted by Michael Wonder on 18 Nov 2020
NICE backs Lilly’s Emgality for migraine, adding pressure on Novartis
18 November 2020 - UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the ...
Posted by Michael Wonder on 12 Nov 2020
NICE recommends innovative treatment for severe blood disorder for NHS use
12 November 2020 - Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura. ...
Posted by Michael Wonder on 11 Nov 2020
NICE publishes draft guidance on new treatment for patients with immune thrombocytopenia
11 November 2020 - The Department of Health and Social Care has asked NICE to produce guidance on using fostamatinib in ...
Posted by Michael Wonder on 10 Nov 2020
NICE recommends new chemotherapy free treatment option for people with untreated chronic lymphocytic leukaemia
10 November 2020 - More than 1,000 people each year will benefit from NICE's recommendation. ...
Posted by Michael Wonder on 09 Nov 2020
NICE issues positive Final Appraisal Determination for AbbVie’s Rinvoq (upadacitinib) in severe active rheumatoid arthritis
6 November 2020 - Positive recommendation means upadacitinib will be available to those with previously treated severe active rheumatoid arthritis. ...